etomoxir has been researched along with 3-(2,2,2-trimethylhydrazine)propionate in 1 studies
| Studies (etomoxir) | Trials (etomoxir) | Recent Studies (post-2010) (etomoxir) | Studies (3-(2,2,2-trimethylhydrazine)propionate) | Trials (3-(2,2,2-trimethylhydrazine)propionate) | Recent Studies (post-2010) (3-(2,2,2-trimethylhydrazine)propionate) |
|---|---|---|---|---|---|
| 260 | 8 | 93 | 251 | 35 | 105 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Maisch, B; Rupp, H; Zarain-Herzberg, A | 1 |
1 review(s) available for etomoxir and 3-(2,2,2-trimethylhydrazine)propionate
| Article | Year |
|---|---|
The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure.
Topics: Acetanilides; Angina Pectoris; Animals; Calcium; Cardiovascular Agents; Clinical Trials as Topic; Enzyme Inhibitors; Epoxy Compounds; Fatty Acids; Gene Expression; Glucose; Heart Failure; Humans; Hypoglycemic Agents; Methylhydrazines; Myocytes, Cardiac; Oxidation-Reduction; Piperazines; Ranolazine; Rats; Rats, Wistar; Sarcoplasmic Reticulum; Trimetazidine; Up-Regulation; Vasodilator Agents | 2002 |